AzTrials
AzTrials

NutritionDIETMICRONCT07672691

Dietary Macronutrients and Gut Microbiota, Inflammation, and Metabolic Markers

A study testing Ketogenic Diet (KD) and Vegetarian Diet (VD) in people with Nutrition and Ketogenic Diet, run by The Jerzy Kukuczka Academy of Physical Education in Katowice at 2 sites in Poland.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This 12-week randomized controlled trial will investigate the effects of dietary patterns with different macronutrient compositions on gut microbiota, intestinal inflammation, gene expression, and metabolic health in healthy adults. Read more about this study

Who is it for?
Ages 18 to 60 yearsHealthy volunteers can take part
Conditions the study is for
Nutrition, Ketogenic Diet, Gene Expression
What is being tested?
Ketogenic Diet (KD) and Vegetarian Diet (VD)
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
200 participants
Where
2 sitesPoland
Study dates
2 Sep 2024to 30 Dec 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • In addition to the physical activity requirements described above, the study will include men and women aged 18-60 years with:
  • BMI not exceeding 40kg/m²
  • Habitual mixed diet prior to study enrollment
  • Normal blood pressure

Who cannot join

  • Poprawiłem już Exclusion Criteria w poprzedniej odpowiedzi - wszystkie te kryteria już tam są wpisane. Oto pełna, ostateczna wersja z wszystkimi wskazanymi kryteriami wyłączenia:
  • Exclusion Criteria:
  • Use of medications regulating glucose levels (e.g., metformin) or blood lipids (e.g., statins)
  • Hypertension or pharmacological treatment for hypertension
  • Diagnosed gastrointestinal disorders, including:
  • Gastric and duodenal ulcers
Show all 20Show fewer
  • Irritable bowel syndrome (IBS)
  • Ulcerative colitis
  • Celiac disease
  • Chronic use of medications such as:
  • Mesalazine
  • Corticosteroids
  • Statins
  • Proton pump inhibitors (PPI)
  • Non-steroidal anti-inflammatory drugs (NSAIDs)
  • Anticonceptional medications
  • Any supplements
  • Alcohol consumption > 2 times/week with > 15 g alcohol per occasion (approximately 15 g alcohol = 330 mL beer, 150 mL dry red wine, or 50 mL vodka)
  • Smoking cigarettes
  • Following a ketogenic diet or vegetarian diet within 1 month prior to study enrollment

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Małgorzata Magdalena Michalczyk, Assistante professor contact

+48535016532

m.michalczyk@awf.katowice.pl

Małgorzata Magdalena Michalczyk, Assistante professor contact

535016532

m.michalczyk@awf.katowice.pl

Poland2 sites, 2 recruiting
  • Jaggielonian University

    Krakow

    Wojciech Branicki, Profesor, 605576336, wojciech.branicki@uj.edu.pl

    Recruiting
  • Pomeranian Medical University

    Szczecin

    Ewelina Pośpiech, Assistance professor, Pomeranian Medical, ewelina.pospiech@pum.edu.pl

    Grzegorz Zydek, Phd, 504332664, g.zydek@awf.katowice.pl

    Recruiting

Other trials in Poland

About this study

Official title: Effects of Diets Differing in Macronutrient Composition on Gut Microbiota Composition, Intestinal Inflammation Markers, Gene Expression Profiles, and Blood Biochemical Parameters in Diverse Populations.

This 12-week randomized controlled trial will investigate the effects of dietary patterns with different macronutrient compositions on gut microbiota, intestinal inflammation, gene expression, and metabolic health in healthy adults.

Participants will be randomly assigned to one of three dietary interventions: a ketogenic diet (KD), a vegetarian diet (VD), or a control diet (CD) reflecting their habitual mixed dietary pattern. Adherence to the assigned diet will be monitored through dietary records and regular nutritional counseling.

Read more

The study will evaluate changes in gut microbiota composition, inflammatory biomarkers, transcriptomic profiles, and blood biochemical parameters associated with lipid and glucose metabolism. Blood and stool samples will be collected at predefined time points throughout the intervention, while participants in the KD group will additionally undergo ketone monitoring to assess dietary compliance.

By comparing the ketogenic and vegetarian diets with a standard mixed diet, this study aims to determine their effects on gut health, metabolic function, and systemic inflammation, thereby providing evidence to inform dietary recommendations.

Read the detailed description

This 12-week randomized controlled trial will evaluate the effects of diets differing in macronutrient composition on gut microbiota, intestinal inflammation markers, gene expression profiles, and blood biochemical parameters. All participants will undergo comprehensive measurements and laboratory assessments at four time points: before the study begins (baseline), after 4 weeks, after 8 weeks, and at 12 weeks (study completion).

At each assessment point (baseline, 4, 8, and 12 weeks), all participants will visit the laboratory in a fasting state and undergo the following measurements:

  1. Body mass and body composition assessment
  2. Transcriptomic analysis
  3. Cellular metabolism studies
  4. Biochemical blood parameters
  5. Gut microbiome analysis

Additionally, participants in the ketogenic diet (KD) group will measure blood ketone levels once weekly throughout the entire study period to monitor dietary adherence. All participants will complete questionnaires assessing stress levels and appetite before, during, and after the study intervention.

Body Mass and Body Composition Measurement

Body composition will be measured on an empty stomach in the supine position using Dual-Energy X-ray Absorptiometry (DEXA). This method utilizes the phenomenon of ionizing radiation beam attenuation as it passes through tissues of different densities. The difference in absorption of two energy levels (43 and 110 keV) by soft tissue and bone tissue enables assessment of both bone mineral density (BMD) and fat tissue content. DEXA is characterized by high accuracy and reproducibility. The examination lasts up to a few minutes, and radiation exposure is minimal. DEXA can be performed during hormonal therapy, hormonal disorders, dietary restrictions, or physical exercise.

Transcriptomic Studies, Cellular Metabolism, Gene Polymorphism, and Biochemical Analyses

For transcriptomic, cellular metabolism, and biochemical studies, 10 mL of venous blood will be collected from the antecubital vein. Simultaneously, at the beginning of the study only, an oral swab will be collected from each participant for gene polymorphism analysis.

Blood and oral swabs will be collected by a nurse at the Functional Examination Laboratory of the Academy of Physical Education in Katowice.

Transcriptomic Analysis

Transcriptomic studies will be conducted in mononuclear blood cells (PBMC) using microarrays. PBMCs will be obtained by centrifuging whole blood in a Ficoll gradient. To obtain sufficient cell quantity, 8 mL of blood will be collected into two 4 mL tubes. The plasma obtained after centrifugation will be stored for biochemical assays and isolation of free-circulating RNA molecules (for potential subsequent studies of selected molecules based on transcriptomic results).

PBMCs will be counted using an automatic cell counter (TC20 cell counter, Biorad) and divided into two parts. From 8 mL of blood, 4-10 mL of live mononuclear cells are obtained. One million cells will be cryopreserved in appropriate medium for subsequent cellular metabolism studies (Seahorse, Agilent). This cell quantity enables performance of each of three possible tests (ATP rate assay, glycolytic rate, mito stress), with test selection based on transcriptomic study results.

Remaining cells will immediately undergo total RNA isolation using the RNeasy Mini Kit (Qiagen) according to the manufacturer's protocol. RNA concentration will be assessed using a Qubit4 fluorometer (Thermo), and integrity using a Bioanalyzer 2100 (Agilent) with RNA 6000 Nano Assay kits (Agilent). Microarray studies require at least 4 μL RNA at 67 ng/μL concentration with RIN coefficient ≥7. From the planned blood quantity, we obtain 200-400 ng/μL in 30 μL volume.

Gene expression will be evaluated using SurePrint G3 Human Gene Expression 8x60K v2 Microarray Kits. The procedure will follow the manufacturer's protocol and include: cDNA synthesis, cRNA synthesis and amplification, sample preparation for hybridization, hybridization (17 h, 65°C), washing, scanning (SureScan, Agilent), and image analysis (Feature Extraction software, Agilent). Results will be analyzed using GeneSpring software.

Cellular Metabolism Analysis

Cellular metabolism studies (ATP-rate assay, Cell Mito Stress, Glycolytic Rate) will be conducted in previously cryopreserved PBMCs using the Seahorse device (Agilent). After thawing, the number of live cells will be counted, then cells will be seeded onto poly-D-lysine-coated measurement plates. Analyses will be performed according to the manufacturer's protocol.

Gene Polymorphism Analysis Related to Macronutrient Metabolism

At study initiation, genetic material will be collected from each participant as an oral swab. This material will be used to analyze polymorphism of genes FTO, GATA3, PPRG2, TCF7L2, ADRB2, APOA2, APOA, and FABP2, associated with protein, fat, and carbohydrate metabolism. The analysis will be performed at Genomix4Life S.r.l. laboratory, a spin-off of the University of Salerno in Italy.

Biochemical Studies

From the 10 mL of blood collected for all studies, 2 mL will be designated for biochemical analyses. The following parameters will be measured:

  • Triacylglycerol (TG, mg/dL)
  • LDL cholesterol (LDL-C, mg/dL)
  • HDL cholesterol (HDL-C, mg/dL)
  • Total cholesterol (tCh, mg/dL)
  • Omega index
  • Glucose (Gl, mg/dL)
  • Glycated hemoglobin (HbA1c, %)
  • Insulin (I, IU/mL)
  • Testosterone (nmol/L)
  • Cortisol (μg/dL)
  • Inflammatory protein (CRP, mg/L)
  • β-hydroxybutyrate (β-HGB, mmol/L)

Additionally, the HOMA-IR index will be calculated using the formula: fasting insulin concentration × fasting glucose concentration / 22.5.

1 mL of blood will be used for serum determination of factors playing essential roles in appetite control: grelin, cholecystokinin (CCK), glucagon-like peptide 1 (GLP-1), leptin, and peptide Y-Y (PYY). These determinations will be performed using ELISA method. Diagnostic kits from Randox (UK), Roche Diagnostic, Diagnostic System Laboratories (Webster, TX, USA), and Beckman Coulter, R\&D, Biotechne will be used. The Omega index will be measured using gas chromatography GC-FID with flame ionization detection.

Ketone Body Measurement as Ketosis Indicator

For ketogenic diet control, participants in the KD group will measure blood ketone levels once weekly, in the morning before breakfast, by collecting 1 drop of blood from the finger using a glucose meter with ketone measurement function (Optimum Xido or Optimum Xido Neo, USA Abbott Laboratories, Chicago, Illinois) or using commercially available urinary ketone test strips (Ketur-Test, Roche Diagnostics, Basel, Switzerland). Results will be discussed with a dietitian during visits at 4, 8, and 12 weeks.

Stool Sample Analysis

On the day of laboratory visit for body mass and composition measurements, participants will deliver biological materials (approximately 10 g of stool) for gut microbiota composition analysis.

Stool microflora analysis will enable qualitative and quantitative assessment of selected bacterial types and species in the gastrointestinal tract. For quantitative analysis of bacteria, yeasts, and molds, a specified stool weight is placed in appropriate volume of liquid culture medium and subjected to careful homogenization (using BagMixer® S\&SW) to achieve homogeneous suspension. From the suspension, a series of 10-fold dilutions is performed, then plated on selective-differential microbiological media.

Bacterial, yeast, and mold cultures are conducted under appropriate conditions:

  • Aerobic bacteria: incubation 24 hours, temperature 37°C, aerobic conditions
  • Anaerobic bacteria: incubation 48-72 hours, temperature 37°C, anaerobic conditions
  • Campylobacter spp.: incubation 72 hours, temperature 42°C, microaerophilic conditions
  • Yeast-like fungi and molds: incubation 48 hours, temperature 37°C, aerobic conditions

After specified incubation time, cultures undergo microbiological diagnostics using culture methods, biochemical methods, and MALDI TOF mass spectrometry. For yeast-like fungi and molds, mycological diagnostics are performed using chromogenic media.

The following microorganisms will be evaluated:

  1. Anaerobic bacteria: Bacteroides spp. and Bifidobacterium spp., Lactobacillus spp. (including hydrogen peroxide-producing strains), proteolytic microflora bacteria: Clostridium spp. (including Clostridium difficile)
  2. Proteolytic microflora bacteria: Campylobacter spp. Aerobic bacteria: Enterococcus spp., Gram-negative E. coli
  3. Proteolytic microflora bacteria: potentially pathogenic E. coli biovar form, Providencia spp., Salmonella spp., Shigella spp., Yersinia spp., Hafnia alvei, Enterobacteriaceae family (Klebsiella spp., Enterobacter spp., Citrobacter spp., Proteus spp., Morganella spp., Serratia spp.), and Pseudomonas spp.
  4. Total bacterial count: Bacillus spp.
  5. Yeast-like fungi: Candida albicans, Candida non-albicans, and mold fungi

Additionally, a sample for qualitative analysis of indicator bacteria using PCR method will be extracted. This assesses presence of enterocyte-feeding bacteria: Akkermansia muciniphila and Fecalibacterium prausnitzii.

In stool samples, inflammatory markers will also be measured: calprotectin, eosinophilic protein X, and alpha-1-antitrypsin.

Being tested
Ketogenic Diet (KD), Vegetarian Diet (VD), Control Diet (CD)
Keywords
ketogenic diet, gene expression, transcriptomics, biochemical parameters, stool microbiome, ketone bodies

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ketogenic Diet (KD)Other

    Participants in the Ketogenic Diet Group (KD) will follow a strict ketogenic diet for 12 weeks. The ketogenic diet is characterized by:

    Fat intake: Approximately 70-80% of total daily energy Carbohydrate intake: Approximately 5-10% of total daily energy (typically <50 g carbohydrates per day) Moderate protein intake: Approximately 15-20% of total daily energy

    Dietary Guidelines:

    Allowed foods: Fatty meats, fish, eggs, full-fat dairy products, butter, oils (olive oil, coconut oil, avocado oil), nuts, seeds, low-carbohydrate vegetables (e.g., leafy greens, broccoli, cauliflower), avocados Restricted foods: All grains (bread, pasta, rice, cereals), high-carbohydrate fruits (bananas, apples, oranges), starchy vegetables (potatoes, corn), legumes, sugar-sweetened foods and beverages, most processed foods Blood ketone levels will be measured once weekly by participants (morning, before breakfast) using a ketone meter (Optimum Xido) Duration: 12 weeks

  • Vegetarian Diet (VD)Other

    Participants in the Vegetarin Diet Group (VD) will follow a plant-based vegetarian diet for 12 weeks. The vegetarin diet excludes all animal products and is characterized by:

    Macronutrient composition: Balanced intake of carbohydrates, proteins, and fats from plant sources

    Primary food sources: Vegetables, fruits, legumes (beans, lentils, peas), nuts, seeds, whole grains, plant-based oils

    Dietary Guidelines:

    Allowed foods: All vegetables, fruits, legumes, nuts, seeds, whole grains (rice, quinoa, oats, wheat), plant-based milks, tofu, tempeh, plant-based oils, avocados Restricted foods: All animal products including meat, poultry, fish, eggs, dairy products, honey, and any food containing animal-derived ingredients Dietary adherence will be monitored through regular food diaries and nutritional counseling sessions

    Participants will receive guidance on adequate protein intake, vitamin B12, iron, calcium, and omega-3 fatty acid supplementation if needed Duration: 12 weeks

  • Control Diet (CD)Other

    Participants in the Control Diet Group (CD) will serve as the control group and will continue their current habitual mixed diet without specific dietary modifications for 12 weeks.

    Diet type: Habitual mixed diet (includes both plant and animal products)

    Macronutrient composition: No modifications; participants maintain their usual dietary intake No dietary restrictions or instructions: Participants are not instructed to change their eating patterns

    Monitoring:

    Dietary intake will be documented through regular food diaries Participants will attend visits with a dietitian at 4, 8, and 12 weeks for monitoring purposes only (no dietary changes instructed) Duration: 12 weeks

Study groups in NCT07672691
Study groupRoleWhat they receive
Ketogenic dietExperimentalParticipants in this arm will follow a ketogenic diet characterized by high fat, very low carbohydrate, and moderate protein intake throughout the 12-week intervention period.
Receives: Other: Ketogenic Diet (KD)
Vegetarian Diet GroupExperimentalParticipants in this arm will follow a plant-based vegan diet excluding all animal products throughout the 12-week intervention period.
Receives: Other: Vegetarian Diet (VD)
Control Diet Group (CD)Placebo comparatorParticipants in this arm will serve as the control group and will continue their current habitual mixed diet without specific dietary modifications throughout the 12-week study period.
Receives: Other: Control Diet (CD)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. β-hydroxybutyrate

    mmol/L

    Measured: 12 weeks

  2. Insulin

    IU/mL

    Measured: 12 weeks

  3. Glucose

    mg/dL

    Measured: 12 weeks

  4. Omega index

    Measured: 12 weeks

  5. HDL cholesterol

    mg/dL

    Measured: 12 weeks

  6. LDL cholesterol

    mg/dL

    Measured: 12 weeks

  7. Triacylglycerol

    mg/dL

    Measured: 12 weeks

  8. Grelin

    ng/mL

    Measured: 12 weeks

  9. cholecystokinin

    pg/mL

    Measured: 12 weeks

  10. glucagon-like peptide-1

    pg/mL

    Measured: 12 weeks

  11. leptin

    ng/mL

    Measured: 12 weeks

  12. peptide YY

    pg/mL

    Measured: 12 weeks

  13. gut microbiome

    CFU/g

    Measured: 12 weeks

  14. Transcriptomic

    log 2fold change

    Measured: 12 weeks

  15. Gene Polymorphism

    allel variance

    Measured: 12 weeks

  16. Total cholesterol

    mg/dL

    Measured: 12 weeks

  17. HbA1c

    Measured: 12 weeks

  18. Testosterone

    nmol/L

    Measured: 12 weeks

  19. Cortisol

    μg/dL

    Measured: 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Jun 2026
  2. Study start2 Sep 2024
  3. Primary completion3 Sep 2024
  4. Study completion30 Dec 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07672691
Sponsor's protocol ID
KB- 2/2021
Other IDs
Institute of Sport Science
Acronym
DIETMICRO
Status last verified
Jul 2026
First submitted
17 Jun 2026
Last updated
21 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Ketogenic Diet (KD) and Vegetarian Diet (VD) in people with Nutrition and Ketogenic Diet, run by The Jerzy Kukuczka Academy of Physical Education in Katowice at 2 sites in Poland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 21 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Małgorzata Magdalena Michalczyk, Assistante professor (+48535016532, m.michalczyk@awf.katowice.pl), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

β-hydroxybutyrate (time frame: 12 weeks). The study lists 19 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in